Compare Ulta Beauty Inc (ULTA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ulta Beauty Inc vs Zimmer Biomet Holdings Inc — how do they compare? Ulta Beauty Inc trades at $570.37 (market cap $24.12B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Ulta Beauty Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ulta Beauty Inc for 92 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ULTA | ZBH | |
|---|---|---|
Market Cap | $24.12B | $16.95B |
Volume | 457,598 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $706.82 | $103.98 |
52-Week Low | $450.75 | $79.58 |
Typical Hold Time | 92 Days | 89 Days |
Enterprise Value | $26.43B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ULTA Beauty trades at $570.02, up 4.5% today, showing strong momentum with a bullish technical setup and positive analyst sentiment. The company delivered Q2 2026 earnings beat ($6.55 actual vs. $6.22 expected) and raised 2026 guidance, supported by robust e-commerce growth. Valuation metrics show a P/E of 20.55 and P/S of 1.92, while profitability remains solid with 39.3% gross margins and 46.1% ROE. Recent news highlights expansion into wellness categories and omnichannel strength.
Outlook remains positive with consensus price target of $624.93 (9.6% upside), though margin pressure and flat store traffic pose execution risks. The stock's current price near resistance at $572 suggests potential near-term consolidation before further gains. Institutional ownership trends show mixed activity with recent CEO share sales offset by pension fund accumulation.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
